These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27522495)

  • 21. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
    Lee MH; Kim J; Kim ST; Shin HM; You HJ; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
    World Neurosurg; 2019 May; 125():e688-e696. PubMed ID: 30735871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
    Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
    Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
    Wang Z; Bao Z; Yan W; You G; Wang Y; Li X; Zhang W
    J Exp Clin Cancer Res; 2013 Aug; 32(1):59. PubMed ID: 23988086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.
    Mandel JJ; Cachia D; Liu D; Wilson C; Aldape K; Fuller G; de Groot JF
    J Neurooncol; 2016 Aug; 129(1):147-54. PubMed ID: 27270908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme.
    Yalaza C; Ak H; Cagli MS; Ozgiray E; Atay S; Aydin HH
    Ann Clin Lab Sci; 2017 May; 47(3):362-364. PubMed ID: 28667042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
    Kim BYS; Jiang W; Beiko J; Prabhu SS; DeMonte F; Gilbert MR; Sawaya R; Aldape KD; Cahill DP; McCutcheon IE
    J Neurooncol; 2014 Jun; 118(2):405-412. PubMed ID: 24777756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.
    Yan W; Zhang W; You G; Bao Z; Wang Y; Liu Y; Kang C; You Y; Wang L; Jiang T
    PLoS One; 2012; 7(1):e30339. PubMed ID: 22291938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 mutation of gliomas with long-term survival analysis.
    Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
    Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
    Cheng HB; Yue W; Xie C; Zhang RY; Hu SS; Wang Z
    Tumour Biol; 2013 Dec; 34(6):3555-9. PubMed ID: 23904262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
    Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
    Lai A; Kharbanda S; Pope WB; Tran A; Solis OE; Peale F; Forrest WF; Pujara K; Carrillo JA; Pandita A; Ellingson BM; Bowers CW; Soriano RH; Schmidt NO; Mohan S; Yong WH; Seshagiri S; Modrusan Z; Jiang Z; Aldape KD; Mischel PS; Liau LM; Escovedo CJ; Chen W; Nghiemphu PL; James CD; Prados MD; Westphal M; Lamszus K; Cloughesy T; Phillips HS
    J Clin Oncol; 2011 Dec; 29(34):4482-90. PubMed ID: 22025148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
    Hodges TR; Choi BD; Bigner DD; Yan H; Sampson JH
    J Neurosurg; 2013 Jun; 118(6):1176-80. PubMed ID: 23581583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Massive dissemination of adult glioblastomas.
    Willard N; Kleinschmidt-DeMasters BK
    Clin Neuropathol; 2015; 34(6):330-42. PubMed ID: 26308254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
    Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.